Recombinant Syntac Polypeptides for Epitope-Specific T-Cell Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current biologic therapies for immune-borne conditions, such as autoimmunity and cancer, lack precision and often cause global immunomodulation, leading to significant toxicity and side effects due to indiscriminate targeting of T cells.
Innovation Solution
Development of recombinant polypeptides that specifically target disease-relevant T cells by combining a candidate epitope peptide with a T cell modulatory domain, linked through specific amino acid sequences and disulfide bonds, allowing for precise upregulation or suppression of T cell activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If global immunomodulation is used to treat immune-borne conditions, then therapeutic coverage is improved, but toxicity and side effects increase due to indiscriminate T cell targeting
Solution Approach 1:
The patent applies local quality by designing recombinant polypeptides with specific epitope peptides that recognize and bind to disease-relevant T cells with high specificity. The polypeptide structure includes an epitope peptide segment (residues 1-20) that selectively targets T cells bearing specific disease-relevant epitopes, thereby providing localized immunomodulation rather than global effects. This selective targeting reduces toxicity while maintaining therapeutic coverage for the specific disease condition.
2Reliability
If costimulatory molecules are used to activate T cells, then T cell activation is improved, but indiscriminate activation leads to global immunostimulation and toxicity
Solution Approach 1:
The patent segments the T cell activation function by dividing the polypeptide into distinct functional segments: an epitope peptide segment (residues 1-20) for specific T cell recognition, a linker region (residues 21-40), and a costimulatory molecule segment (residues 41-100). This segmentation allows the costimulatory function to be delivered selectively to epitope-specific T cells rather than activating all T cells globally, thereby improving reliability of activation while reducing harmful global effects.
Solution Approach 2:
The recombinant polypeptide acts as an intermediary molecule that bridges the epitope-specific T cell and the costimulatory signal. The polypeptide binds to the T cell receptor with high affinity through the epitope peptide segment, then delivers the costimulatory signal through the costimulatory molecule segment. This intermediary mechanism ensures that costimulation occurs only in the context of specific epitope recognition, preventing indiscriminate T cell activation.
3Measurement precision
If first generation targeted biologics are used to direct effects on T cell subsets, then targeting precision is improved, but inability to target only disease-relevant cells remains
Solution Approach 1:
The patent changes the targeting parameter from broad T cell subset targeting to epitope-specific T cell targeting. The epitope peptide segment is designed to recognize specific peptide antigens presented by MHC molecules on disease-relevant cells. By changing the specificity parameter from general T cell surface markers to epitope-specific recognition, the system achieves both high targeting precision and reliable disease-relevant cell targeting simultaneously.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables targeted modulation of T cell activity, reducing toxicity and side effects while enhancing therapeutic efficacy for autoimmune disorders and cancer treatment.
Implementation Method 1
combining a candidate epitope peptide with a T cell modulatory domain, linked through specific amino acid sequences and disulfide bonds
Data Source
AI summary
Methods and compositions for clonally inhibiting or clonally stimulating T-cells are provided.